A multiomic approach to prediction, causation, and prevention of preterm birth and preeclampsia
A multiomic approach to prediction, causation, and prevention of preterm birth and preeclampsia
Recent advances in both genomics, transcriptomics, and proteomics have allowed for the development of novel technologies with greater capabilities for biomarker profiling and discovery. When coupled with high-content data analysis, these multiomic approaches have allowed researchers to generate high-efficiency data to enable new correlations and insights between the genome, transcriptome, and proteome at a molecular level in health and disease. For example, an area of unmet need where multiomics is poised to impact significantly is pregnancy-related complications, such as preterm birth and preeclampsia. A better understanding of the molecular mechanisms of feto-maternal changes during pregnancy could help save lives and improve birthing processes.
Our distinguished presenters — members of the Gaudillière lab at Stanford University — describe how they employed a translational approach that combines single-cell mass cytometry with high-plex proteomic and metabolomic analyses to study the role of the human immune system in the pathobiology of fundamental clinical problems, including pregnancy pathologies. The presenters also explain how they used novel machine-learning methods to train multiomic models and identify biologically relevant predictive biomarkers to develop robust diagnostics rooted in a precise understanding of underlying pathobiological mechanisms.
Ina Stelzer, PhD
Instructor
Stanford University
Julien Hédou, MSc
Data Analyst
Stanford University
Dorien Feyaerts, PhD
Postdoctoral Fellow
Stanford University
A multiomic approach to prediction, causation, and prevention of preterm birth and preeclampsia
A presentation by Ina Stelzer, PhD, Julien Hédou, MSc, and Dorien Feyaerts, PhD
More webinars
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.
WebinarFrom discovery to clinical insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing. Watch this presentation given by Maik Pietzner, PhD, at ESHG 2024.